Prostate Cancer

The use of moderately hypofractionated radiation therapy demonstrated no statistically significant differences in functional outcomes compared with conventionally fractionated radiation therapy, further cementing hypofractionated radiation therapy as a standard approach for patients with nonmetastatic prostate cancer.

Thomas Powles, MD, MBBS, MRCP, discusses the mission and goals for the Uromigos Twitter group.

Rana R. McKay, MD, discusses the results of a real-world analysis of radium-223 in patients with metastatic castration-resistant prostate cancer.

Neeraj Agarwal, MD, discusses the importance of developing biomarkers of response to the combination of cabozantinib and atezolizumab in patients with metastatic castration-resistant prostate cancer.

Julie N. Graff, MD, discusses the results of the phase II KEYNOTE-199 trial in metastatic castration-resistant prostate cancer.

William K. Oh, MD, discusses remaining challenges with the advancing treatments in prostate cancer.

Petros Grivas, MD, discusses comparisons between ATM and BRCA1/2 mutations in metastatic castration-resistant prostate cancer.

Martin T. King, MD, PhD, discusses the INTREPId trial exploring darolutamide plus radiation therapy in patients with prostate cancer.

Neoadjuvant and concurrent androgen-deprivation therapy (ADT) with dose-escalated prostate radiotherapy (PRT) and concurrent and adjuvant ADT plus dose-escalated PRT were found to have no statistically significant differences in biochemical relapse-free survival in patients with localized prostate cancer, according to results of a phase III trial.

Scott T. Tagawa, MD, MS, discusses preliminary data with 225Ac-J591 in metastatic castration-resistant prostate cancer.

Andrew J. Armstrong, MD, discusses the rationale of the PROPHECY trial in metastatic castration-resistant prostate cancer.

Christina Tan, MD, MPH, discusses the potential impact of the novel coronavirus on patients with cancer.

Wolfgang Fendler, MD, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at University of California, Los Angeles, discusses the clinical need for 68Ga-PSMA-11 PET in biochemically recurrent prostate cancer.

Julie N. Graff, MD, discusses the multi-cohort, phase II KEYNOTE-199 study examining patients with metastatic castration-resistant prostate cancer.

William L. Dahut, MD, discusses the natural history trial, the implications of the PROfound study, and the importance of screening for men at a high risk for developing prostate cancer.

The combination of cabozantinib and atezolizumab demonstrated clinically meaningful activity in patients with metastatic castration-resistant prostate cancer, including those with high-risk clinical features.

Sumanta K. Pal, MD, discusses the rationale for adding cabozantinib to atezolizumab in prostate cancer.

Stephen J. Freedland, MD, discusses a real-world analysis of enzalutamide in metastatic castration-resistant prostate cancer.

Daniel P. Petrylak, MD, discusses important new developments in bladder and prostate cancer.

Emmanuel S. Antonarakis, MBBCh, professor of oncology, Johns Hopkins Medicine, discusses a phase II trial evaluating the combination of sipuleucel-T (Provenge) plus radium-223 dichloride (Xofigo) versus sipuleucel-T alone in patients with asymptomatic bone-metastatic castrate-resistant prostate cancer (mCRPC).

Carlos E. Vargas, MD, examines the use of stereotactic body radiation therapy (SBRT) in oligometastatic prostate cancer.